A retrospective observational study of predictors of adverse maternal and fetal outcomes in mothers with systemic lupus erythematosus in pregnancy
DOI:
https://doi.org/10.18203/2320-1770.ijrcog2026%202100Keywords:
Adverse pregnancy outcomes, Binder’s facies, Congenital heart block, SLEAbstract
Background: SLE is a disease of reproductive age group and has implications on maternal and fetal health in pregnancy. This study was done to determine and analyze the predictors of adverse maternal and fetal outcomes in mothers with systemic lupus erythematosus in pregnancy.
Methods: Retrospective observational study was done to evaluate pregnancy outcomes in SLE mothers at Fernandez Hospital, Hyderabad, from January 2017 to December 2022. Data was obtained via electronic medical records. Descriptive analysis was done by mean and standard deviation for quantitative variables, and frequency and proportion for categorical variables. Chi-square test was used to test statistical significance between variables (p<0.05 was significant).
Results: SLE affects pregnancies causing adverse maternal (flares (18.95%), hypertensive disorders (22.18%), severe maternal morbidity (5.65%), fetal (preterm birth (38.71%), FGR (28.97%), perinatal death (3.17%)), and neonatal (congenital heart block (3.17%), neonatal lupus (3.96%), Binder’s facies (5.16%)) outcomes- especially when period of remission was <6 months (p<0.05). Anti-Smith, RNP and Scl-70 Ab were significantly associated with Binder’s facies and chondrodysplasia. Anti-Ro/La antibodies were associated with congenital heart block and endocardial fibroelastosis. Lupus nephritis was an independent risk factor for adverse outcomes. Chronic hypertension, past history of thrombosis and chronic kidney disease were risk factors for adverse outcomes (p<0.05). Heparin, HCQs and Azathioprine could also have a role in improving perinatal outcomes (p<0.05).
Conclusions: As SLE can cause adverse maternal, fetal and perinatal outcomes in pregnancy, all mothers with SLE should undergo preconceptional counselling to optimize outcomes.
References
Silver R, Craigo S, Porter F, Osmundson SS, Kuller JA, Norton ME, et al. Society for Maternal-Fetal Medicine Consult Series# 64: Systemic lupus erythematosus in pregnancy. Am J Obstet Gynecol. 2023;228(3):B41-60.
Malaviya AN, Singh RR, Singh YN, Kapoor SK, Kumar A. Prevalence of systemic lupus erythematosus in India. Lupus. 1993;2(2):115-8.
Dema B, Charles N. Advances in mechanisms of systemic lupus erythematosus. Discov Med. 2014;17(95):247-55.
Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arth Rheumatol. 2019;71(9):1400-12.
Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arth Rheum. 2012;64(8):2677-86
Meng C, Lockskin M. Pregnancy in lupus. Curr Opin Rheumatol. 1999;11:348-51.
Buyon JP, Hiebert R, Copel J, Craft J, Friedman D, Katholi M, et al. Autoimmune associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol. 1998;31(7):1658-66
Nelissen E, Mduma E, Broerse J, Ersdal H, Evjen-Olsen B, van Roosmalen J, et al. Applicability of the WHO maternal near miss criteria in a low-resource setting. PloS One. 2013;8(4):e61248.
Ong SG, Ding HJ. Predictors of adverse pregnancy outcome in a cohort of women with systemic lupus erythematosus in Malaysia. Med J Malay. 2021;76(4):466-73.
Ko HS, Ahn HY, Jang DG, Choi SK, Park YG, Park IY, et al. Pregnancy outcomes and appropriate timing of pregnancy in 183 pregnancies in Korean patients with SLE. Int J Med Sci. 2011;8(7):577.
Buyon JP, Kim MY, Guerra MM, et al. Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Int Med. 2015; 163:153-63.
Stojan G, Baer AN. Flares of systemic lupus erythematosus during pregnancy and the puerperium: prevention, diagnosis and management. Expert Rev Clin Immunol. 2012;8(5):439-53.
Singh N, Sabo J, Crane DA, Doody DR, Schiff MA, Mueller BA. Birth outcomes and re‐hospitalizations among pregnant women with rheumatoid arthritis and systemic lupus erythematosus and their offspring. Arth Care Res. 2023.
Zamani B, Shayestehpour M, Esfahanian F, Akbari H. The study of factors associated with pregnancy outcomes in patients with systemic lupus erythematosus. BMC Res Notes. 2020;13(1):185
Nield LE, Silverman ED, Taylor GP, Smallhorn JF, Mullen JBM, Silverman NH, et al. Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis. Circulation. 2002;105:843-8.
Zuppa AA, Riccardi R, Frezza S, Gallini F, Luciano RMP, Alighieri G, et al. Neonatal lupus: Follow-up in infants with anti -SSA/Ro antibodies and review of the literature. Autoimmun Rev. 2017;16:427-32.
Leroux M, Desveaux C, Parcevaux M, Julliac B, Gouyon JB, Dallay D, et al. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. Lupus. 2015;24(13):1384-91.
Izmirly P, Kim M, Friedman DM, Costedoat-Chalumeau N, Clancy R, Copel JA, et al. Hydroxychloroquine to prevent recurrent congenital heart block in fetuses of anti-SSA/Ro-positive mothers. J Am Coll Cardiol. 2020;76(3):292-302.
Vinet É, Pineau CA, Scott S, Clarke AE, Platt RW, Bernatsky S. Increased congenital heart defects in children born to women with systemic lupus erythematosus: results from the offspring of Systemic Lupus Erythematosus Mothers Registry Study. Circulation. 2015;131(2):149-56.
Roy A, De P, Chakraborty S. Rhizomelic chondrodysplasia punctata with maternal systemic lupus erythromatosus. Indian Pediatr. 2013;50(6):605-7.
Chitayat D, Keating S, Zand DJ, Costa T, Zackai EH, Silverman E, et al. Chondrodysplasia punctata associated with maternal autoimmune diseases: expanding the spectrum from systemic lupus erythematosus (SLE) to mixed connective tissue disease (MCTD) and scleroderma report of eight cases. Am J Med Genet Part A. 2008 D;146(23):3038-53.
Schulz SW, Bober M, Johnson C, Braverman N, Jimenez SA. Maternal mixed connective tissue disease and offspring with chondrodysplasia punctata. Semin Arth Rheumat. 2010;39(5):410-6.
Downloads
Published
How to Cite
Issue
Section
